113.08
price up icon1.56%   1.74
 
loading
Biontech Se Adr stock is traded at $113.08, with a volume of 863.98K. It is up +1.56% in the last 24 hours and up +10.71% over the past month. BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
See More
Previous Close:
$111.34
Open:
$110.76
24h Volume:
863.98K
Relative Volume:
1.05
Market Cap:
$27.11B
Revenue:
$3.30B
Net Income/Loss:
$-501.07M
P/E Ratio:
9.8003
EPS:
11.5384
Net Cash Flow:
$1.03B
1W Performance:
-6.06%
1M Performance:
+10.71%
6M Performance:
+31.67%
1Y Performance:
+10.00%
1-Day Range:
Value
$109.80
$115.34
1-Week Range:
Value
$109.52
$119.64
52-Week Range:
Value
$76.53
$131.49

Biontech Se Adr Stock (BNTX) Company Profile

Name
Name
Biontech Se Adr
Name
Phone
-
Name
Address
-
Name
Employee
6,133
Name
Twitter
@BioNTech_Group
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
BNTX's Discussions on Twitter

Compare BNTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62

Biontech Se Adr Stock (BNTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-11-24 Initiated Wells Fargo Overweight
Dec-02-24 Reiterated BMO Capital Markets Outperform
Nov-19-24 Initiated Berenberg Buy
Nov-19-24 Upgrade Evercore ISI In-line → Outperform
Nov-08-24 Upgrade Goldman Neutral → Buy
Sep-24-24 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-17-24 Upgrade Jefferies Hold → Buy
Sep-16-24 Upgrade JP Morgan Underweight → Neutral
Aug-07-24 Upgrade Deutsche Bank Hold → Buy
Aug-02-24 Upgrade HSBC Securities Hold → Buy
May-14-24 Initiated Evercore ISI In-line
Feb-23-24 Initiated BMO Capital Markets Outperform
Jan-05-24 Initiated Oppenheimer Perform
Dec-01-23 Downgrade JP Morgan Neutral → Underweight
Oct-16-23 Downgrade HSBC Securities Buy → Hold
Jul-14-23 Initiated HSBC Securities Buy
May-17-23 Upgrade Redburn Neutral → Buy
Dec-15-22 Upgrade BofA Securities Neutral → Buy
Aug-17-22 Initiated Cowen Market Perform
Jul-13-22 Upgrade SVB Leerink Mkt Perform → Outperform
Jul-06-22 Resumed Canaccord Genuity Buy
Feb-01-22 Upgrade Redburn Sell → Neutral
Dec-16-21 Initiated Morgan Stanley Equal-Weight
Nov-10-21 Upgrade H.C. Wainwright Neutral → Buy
Oct-22-21 Initiated Deutsche Bank Hold
Oct-07-21 Initiated Jefferies Hold
Aug-11-21 Upgrade Bryan Garnier Neutral → Buy
Jul-19-21 Resumed Wolfe Research Outperform
Jun-16-21 Downgrade Redburn Neutral → Sell
May-18-21 Initiated Goldman Neutral
May-11-21 Downgrade Bryan Garnier Buy → Neutral
Dec-01-20 Downgrade BofA Securities Buy → Neutral
Aug-03-20 Resumed Berenberg Buy
Jul-21-20 Upgrade BofA Securities Neutral → Buy
Jun-30-20 Downgrade H.C. Wainwright Buy → Neutral
May-19-20 Upgrade H.C. Wainwright Neutral → Buy
Apr-28-20 Downgrade BofA/Merrill Buy → Neutral
Mar-18-20 Downgrade JP Morgan Overweight → Neutral
Mar-09-20 Initiated H.C. Wainwright Neutral
Jan-24-20 Downgrade SVB Leerink Outperform → Mkt Perform
Jan-22-20 Downgrade UBS Buy → Neutral
Nov-05-19 Initiated Wolfe Research Outperform
Nov-04-19 Initiated Berenberg Buy
Nov-04-19 Initiated BofA/Merrill Buy
Nov-04-19 Initiated Canaccord Genuity Buy
Nov-04-19 Initiated JP Morgan Overweight
Nov-04-19 Initiated SVB Leerink Outperform
Nov-04-19 Initiated UBS Buy
View All

Biontech Se Adr Stock (BNTX) Latest News

pulisher
Dec 19, 2024

BioNTech SE ADR falls Thursday, underperforms market - MarketWatch

Dec 19, 2024
pulisher
Dec 18, 2024

BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch

Dec 18, 2024
pulisher
Dec 18, 2024

3 No-Brainer Biotech Stocks to Buy With $200 Right Now - The Motley Fool

Dec 18, 2024
pulisher
Dec 18, 2024

Stocks Generating Improved Relative Strength: BioNTech ADR - Investor's Business Daily

Dec 18, 2024
pulisher
Dec 17, 2024

BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch

Dec 17, 2024
pulisher
Dec 16, 2024

BioNTech SE ADR falls Monday, underperforms market - MarketWatch

Dec 16, 2024
pulisher
Dec 16, 2024

BioNTech's SWOT analysis: mRNA pioneer's stock faces oncology pipeline test - Investing.com

Dec 16, 2024
pulisher
Dec 13, 2024

BioNTech SE ADR falls Friday, underperforms market - MarketWatch

Dec 13, 2024
pulisher
Dec 12, 2024

BioNTech SE ADR rises Thursday, outperforms market - MarketWatch

Dec 12, 2024
pulisher
Dec 11, 2024

BioNTech SE ADR rises Wednesday, outperforms market - MarketWatch

Dec 11, 2024
pulisher
Dec 10, 2024

BioNTech SE ADR falls Tuesday, underperforms market - MarketWatch

Dec 10, 2024
pulisher
Dec 06, 2024

BioNTech SE ADR rises Friday, outperforms market - MarketWatch

Dec 06, 2024
pulisher
Dec 03, 2024

BioNTech's SWOT analysis: mRNA pioneer's stock balances COVID legacy, oncology future - Investing.com

Dec 03, 2024
pulisher
Nov 25, 2024

BioNTech SE ADR rises Monday, outperforms market - MarketWatch

Nov 25, 2024
pulisher
Nov 25, 2024

Stocks Showing Improving Market Leadership: BioNTech ADR Earns 81 RS Rating - Investor's Business Daily

Nov 25, 2024
pulisher
Nov 22, 2024

BioNTech ADR Earns Relative Strength Rating Upgrade - Investor's Business Daily

Nov 22, 2024
pulisher
Nov 21, 2024

BioNTech's SWOT analysis: oncology pipeline fuels stock's potential amid market volatility - Investing.com

Nov 21, 2024
pulisher
Nov 20, 2024

BioNTech Stock Got A IBD RS Rating Lift - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

BioNTech ADR Shows Improved Relative Strength; Still Shy Of Benchmark - Inkl

Nov 20, 2024
pulisher
Nov 19, 2024

Analysts Turn Bullish on BioNTech Stock Amid Volatility - Schaeffers Research

Nov 19, 2024
pulisher
Nov 18, 2024

10 Biggest Biotechnology Companies - Investopedia

Nov 18, 2024
pulisher
Nov 16, 2024

BioNTech SE ADR (BNTX): An Important Analyst Insights - Stocks Register

Nov 16, 2024
pulisher
Nov 15, 2024

Powell Speaks The Truth - Benzinga

Nov 15, 2024
pulisher
Nov 15, 2024

Goodwin, Conyers, A&O Shearman Act on $800M China Biotech Sale - Law.com International

Nov 15, 2024
pulisher
Nov 14, 2024

BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up - Yahoo Finance

Nov 14, 2024
pulisher
Nov 08, 2024

Stock Futures Quiet as Market Heads for Winning Week - Schaeffers Research

Nov 08, 2024
pulisher
Nov 05, 2024

BioNTech Earnings: Strong Covid Revenue, but Full-Year Expectations Unchanged - Morningstar

Nov 05, 2024
pulisher
Nov 04, 2024

BioNTech SE Reports Strong Q3 2024 Results - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

This 6%-yielding U.S. pharma giant is a safe hold - The Globe and Mail

Nov 04, 2024
pulisher
Nov 04, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Nov 04, 2024
pulisher
Oct 31, 2024

BioNTech SE ADR outperforms market despite losses on the day - MarketWatch

Oct 31, 2024
pulisher
Oct 29, 2024

Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase - Yahoo Finance

Oct 29, 2024
pulisher
Oct 28, 2024

Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings? - Nasdaq

Oct 28, 2024
pulisher
Oct 28, 2024

BioNTech to Report Q3 Earnings: Is a Beat in the Cards? - MSN

Oct 28, 2024

Biontech Se Adr Stock (BNTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$245.44
price up icon 2.75%
$176.50
price up icon 1.02%
$623.82
price down icon 0.35%
$359.58
price down icon 0.16%
$39.39
price down icon 0.43%
Cap:     |  Volume (24h):